Skip to Content

Detecting Cell Loss in Diabetes

A new PET marker can spot damage earlier, improving treatment.
June 25, 2007

A novel molecular tracer could help doctors track the loss of insulin-producing cells in diabetes. Such a tool would allow both doctors and drug developers to better assess the effectiveness of new treatments. It could also shed light on the disease by allowing scientists to correlate loss of insulin-producing cells with diabetes symptoms for the first time.

Tracking diabetes: A molecular marker that labels insulin-producing cells could allow doctors to track cell loss in diabetes. This image shows a rat that has been injected with the marker. The pancreas, where the insulin-producing cells reside, is highlighted in bright blue by the marker.

“If we could see cell loss early, perhaps we could get patients started on therapy before there is irreversible damage,” says Dan Skovronsky, founder and CEO of Philadelphia-based Avid Radiopharmaceuticals, the company that is developing the marker.

Type 1 diabetes and late-stage type 2 diabetes are characterized by the loss of the insulin-producing cells in the pancreas. Scientists estimate that people diagnosed with type 1 diabetes have already lost approximately 50 to 90 percent of their insulin-producing cells by the time they begin to show symptoms. “Insulin measurements are only reliable when it’s too late–when the disease is well advanced,” says Paul Harris, a biologist at Columbia University, in New York. “Patients are losing cells silently.”

Because these cells are relatively rare in the pancreas, tracking them in patients has historically been difficult. “They only make up about 1 percent of the cells in the pancreas, so you really need something molecularly targeted to see them,” says Skovronsky.

Avid’s marker, originally developed by Hank Kung, a scientist at the University of Pennsylvania, in Philadelphia, shows promise in animal studies. It binds to a receptor on the surface of the insulin-producing cells; the marker is tagged with a radioactive label so that it can be detected using positron emission tomography, or PET imaging. This type of imaging is currently used to locate tumors and assess brain and heart function.

The marker can successfully distinguish between the pancreases of healthy rats and those whose insulin-producing cells have been destroyed, according to results presented at the Society of Nuclear Medicine’s annual meeting in Washington, DC, earlier this month. Kung now plans to test the marker in additional animal models of diabetes to show that it can track more-gradual changes in the number of insulin-producing cells, as is likely to occur in human diabetes.

The researchers say that pharmaceutical companies have already expressed interest in using the marker in clinical trials of new drugs designed to regenerate insulin-producing cells.

The test might also help identify at the earliest stages those at risk of diabetes, such as people with a family history of the disease and pregnant women with other risk factors for gestational diabetes–in other words, people who might benefit from protective therapies currently in development.

The PET marker was originally developed to target brain cells, and it’s now in early-stage clinical trials for people with neurodegenerative disease. (For reasons not yet clear to scientists, brain cells and pancreatic cells share many molecular markers.) Skovronsky says that testing for diabetes is likely to move forward quickly because the compound has already gone through safety studies and has regulatory approval from the FDA. Avid aims to begin diabetes testing this year.

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.